Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.69 |
| ▸ | DPP4 | P27487 | 17/20 | 0.68 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.68 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.59 |
| ▸ | FAP | Q12884 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075942 | 1.00 | DPP7 (0.69) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL5872039 | 0.94 | DPP4 (0.67) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL8274082 | 0.88 | DPP4 (0.66) | DPP7DPP4DPP8DPP9FAP | |
| Trifluoroacetic Acid SCHEMBL5871430 | 0.88 | DPP4 (0.61) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6824833 | 0.82 | DPP7 (1.00) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL6824830 | 0.82 | DPP7 (1.00) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL160102 | 0.81 | DPP4 (1.00) | DPP7DPP4DPP8 | |
| SCHEMBL29416829 | 0.81 | DPP4 (1.00) | DPP7DPP4DPP8 | |
| SCHEMBL220478 | 0.81 | DPP4 (1.00) | DPP7DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL356225 | 0.80 | DPP4 (0.98) | DPP7DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | disclosed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1496877-A2 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK A/S (DK) | 2005-01-19 | — | — | EP | disclosed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | DPP7 3/4885DPP4 1/4885DPP8 8/4885 |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | DPP7 5/4885DPP4 1/4885DPP8 8/4885 |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | DPP7 5/4885DPP4 1/4885DPP8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.